UPDATE 3-Eli Lilly misses sales estimates as top-seller Trulicity disappoints
Eli Lilly and Co's quarterly sales missed Wall Street estimates on Wednesday as the drugmaker offered more discounts or rebates for its top-selling diabetes drug Trulicity, sending shares down 3%. [Source]
Publication Date:Origin: reuters.com
Category: companyNews
Topics: Trulicity, estimates, Lilly, shares, sending, diabetes drug, top-selling, rebates, discounts, drugmaker offered, Street, missed, quarterly sales, disappoints, top-seller, sales, misses, 3-Eli, UPDATE